Target intelligence / Profile preview

Histone deacetylase 3 (HDAC3) (HDAC3)

Target
HDAC3
Molecular classification
Enzyme, Histone modification, Class I histone deacetylase
01

Overview

Histone deacetylase 3 (HDAC3) is a Class I enzyme that plays a pivotal role in the epigenetic regulation of gene expression by removing acetyl groups from lysine residues on histones and various non-histone proteins (UniProt O15379). It is unique among Class I HDACs because its enzymatic activity is strictly dependent on its association with the NCoR (nuclear receptor corepressor) and SMRT (silencing mediator for retinoid and thyroid receptors) complexes, as well as the presence of the signaling molecule inositol tetraphosphate (Lahm et al., 2007). HDAC3 is involved in a wide array of biological processes, including cell cycle progression, apoptosis, and metabolic regulation, particularly in the liver and heart (Sun et al., 2013). Dysregulation or overexpression of HDAC3 is frequently observed in various malignancies, where it contributes to the silencing of tumor suppressor genes and promotes oncogenic pathways (NCBI Gene 8841). Sodium butyrate is a short-chain fatty acid that acts as a non-selective inhibitor of HDAC3 and other Class I and II HDACs, and it is often used in research to study the effects of histone hyperacetylation on cell differentiation and growth arrest (PubChem CID 522249). Therapeutic targeting of HDAC3 aims to reverse aberrant epigenetic silencing, though achieving isoform selectivity remains a significant challenge in drug development.

Other names
HD3RPD3-2SMAP45Histone deacetylase 3
02

Mechanism of action

HDAC3 catalyzes the deacetylation of lysine residues on histone tails (H3 and H4) and non-histone proteins, facilitating a condensed chromatin state that generally represses transcription (UniProt O15379).

03

Biological functions

Gene expression regulationChromatin remodelingCell cycle regulationApoptosisMetabolic homeostasis
04

Disease associations

CancerInflammationNeurodegenerative diseaseDiabetesCardiovascular disease
05

Safety considerations

Hematological toxicity (e.g., thrombocytopenia)Gastrointestinal side effectsPotential for off-target effects with non-selective inhibitorsCardiac toxicity (QT prolongation)
06

Interacting drugs

Sodium butyrate

5 more in the full profile.

07

Biomarkers

Histone H3K9 acetylation levelsHDAC3 protein expressionp21/WAF1 (CDKN1A) expression levels

Beyond the preview

Go deeper on Histone deacetylase 3 (HDAC3) (HDAC3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Histone deacetylase 3 (HDAC3) (HDAC3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call